{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 73 of 92', 'CR845-CLIN3102', 'Exploratory analyses may be performed, depending on sample size, for the subgroup of', 'patients who also stop taking concomitant opioid medications during the 2-week', 'Discontinuation Period.', 'Adverse events (AEs) and vital signs potentially related to withdrawal that occur during', 'the 2-week Discontinuation Period will be identified based on a blinded review of the', 'data, and will be summarized by randomized treatment group, and compared to the', '2-week period prior to discontinuation,', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 75 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 74 of 92', 'CR845-CLIN3102', '9.0', 'Quality Control and Quality Assurance', '9.1', 'Study Monitoring Plan', 'Monitoring and auditing procedures that comply with current Good Clinical Practice', '(GCP) guidelines will be followed, including remote and onsite review of the eCRFs via', 'an electronic data capture system for completeness and clarity, source document', 'verification, evaluation of protocol adherence, appropriate documentation of informed', 'consent procedures, safety reporting, study drug storage, and dispensation. The study', 'will be monitored by Cara Therapeutics or its designee (contract research organization).', 'Monitoring will be done remotely or by personal visits from a representative of the', 'Sponsor or its designee (site monitor) who will review patient enrollment, eCRFs, source', 'documents, drug accountability records, and reporting and recording of adverse events.', 'The site monitor will ensure that the investigation is conducted according to protocol', 'design and regulatory requirements by frequent site visits and communications (letter,', 'telephone, and facsimile).', 'The site monitor(s) will follow written standard operating procedures as agreed with the', 'contract research organization and the Sponsor. The site monitor(s) will verify that the', 'clinical study is conducted and data are generated, documented (recorded), and reported', 'in compliance with the protocol, GCP, and the applicable regulatory requirements.', 'Monitoring reports will be submitted to the Sponsor in a timely fashion as per details', 'described in a clinical monitoring plan for this study.', 'Name and contact information for monitors will be included in the ISF.', 'An IDMC will be convened for this study to implement an unblinded sample size', 're-estimation. In addition, there will be a DSMB that will convene periodically to assess', 'accumulating safety data. Membership into the IDMC will be independent of', 'membership into the DSMB. A contract organization specializing in IDMC management', \"will be identified. The IDMC and the DSMB will be supported on the Sponsor's behalf\", 'by an independent unblinded statistician who will not be part of the study team. Details', 'will be in the IDMC and DSMB charters.', 'Clinical laboratory testing will be completed at a central laboratory. The central', 'laboratory will provide a separate manual.', '9.2', 'Audits and Inspections', 'The investigational site will maintain appropriate medical and research records for this', 'study, in compliance with ICH-GCP, regulatory, and institutional requirements for the', 'protection of confidentiality of participants. The Investigator must allow access to', 'authorized persons or institutions to complete data source verification. Source data are', 'all information, original records of clinical findings, observations, or other activities in a', 'clinical study necessary for the reconstruction and evaluation of the study. Examples of', 'these original documents and data records include, but are not limited to, hospital records,', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 76 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 75 of 92', 'CR845-CLIN3102', \"clinical and office charts, laboratory notes, memoranda, participants' diaries or evaluation\", 'checklists, pharmacy dispensing records, recorded data from automated instruments,', 'copies or transcriptions certified after verification as being accurate and complete,', 'microfiches, photographic negatives, microfilm or magnetic media, x-rays, and', 'participant files and records kept at the pharmacy, laboratories, or medical-technical', 'departments involved in the clinical study, as applicable.', 'The investigational site will provide access to all study-related sites, source', 'data/documents, and reports for the purpose of monitoring and auditing by the Sponsor', 'and inspection by local and regulatory authorities.', '9.3', 'Data Collection, Validation, and Analysis', 'A data management vendor will ensure that quality assurance procedures are', 'implemented, beginning with the data entry system and generation of data quality control', 'checks that will be run on the database.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 77 of 95']\n\n###\n\n", "completion": "END"}